Guzip Biomarkers Corporation
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Guzip’s flagship products include MPap® and RitaPap®, both of which use methylation-specific qPCR to detect methylation status of key genes; MPap uses cervical scrape samples, while RitaPap uses tampon-collected samples.
They also develop a MUrine test (
They also develop a MUrine test (
The content above was translated by Ai
Founded Year
2018
Unified Business No.
50859246
Status
Active
Number of Employees
10
Total Paid-in
Capital
38,723,910 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Acquired(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Guzip Biomarkers Corporation, founded in 2018 as a spin‑out from Taipei Medical University, is a research‑driven biotech company specializing in epigenetics and DNA methylation.
Their mission is to develop novel methylation‑based biomarkers for clinical applications, particularly in women’s health.
Their mission is to develop novel methylation‑based biomarkers for clinical applications, particularly in women’s health.
The content above was translated by Ai
Corporate Video
